Theravance Biopharma Inc.

TBPH

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 208,771Value: $3.9M

# Signal Note: Rock Springs Capital Initiates TBPH Position Rock Springs' $3.9M initiation in TBPH likely reflects conviction in the company's respiratory pipeline, particularly Yaminiplustat (ORCA-3) in COPD, which completed Phase 2b dosing in 2024. The timing suggests positioning ahead of upcoming efficacy readouts expected in H1 2025, a key inflection point for the company's clinical value.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS1 fund NBIX1 fund OLMA1 fund MIRM1 fund AMLX1 fund NAMSW1 fund OMDA1 fund REGN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: